Genentech and NVIDIA Establish Strategic Collaboration for AI Research to Enhance Drug Discovery and Development
Wednesday, November 22, 2023
Genentech, a member of the Roche Group, has recently unveiled a strategic research partnership with NVIDIA, a global leader in accelerated computing and artificial intelligence (AI). The collaboration is designed to leverage Genentech's AI capabilities, vast biological and molecular datasets, and research expertise, in conjunction with NVIDIA's powerful computing capabilities, to expedite drug discovery and development.
The goal is to enhance Genentech's advanced AI research programs by evolving generative AI models and algorithms into a cutting-edge AI platform. As part of this collaboration, Genentech will accelerate and optimize its proprietary machine learning (ML) algorithms and models using the NVIDIA DGX Cloud, a training-as-a-service platform built on dedicated AI supercomputing infrastructure.
NVIDIA will share its computing expertise with Genentech's computational scientists to optimize and scale Genentech's models, potentially leading to improvements in NVIDIA's platforms. The collaboration aims to fast-track the discovery and delivery of novel therapies and medicines by combining Genentech's scientific data and experiments with NVIDIA's accelerated computing capabilities.
Genentech Research and Early Development, emphasized the impact of integrating AI models and algorithms with unique data and experiments to unlock scientific discoveries at an unprecedented scale. The collaboration aligns with Genentech's commitment to integrating science and technology for biomedical breakthroughs.
NVIDIA, highlighted the transformative potential of generative AI in revolutionizing the life science and healthcare industry. The collaboration aims to create Genentech's next-generation AI platform, accelerating the pace of drug discovery and development.
Genentech's AI/ML teams, focused on various therapeutic modalities, will benefit from the collaboration, helping glean new insights for target and drug discovery. The partnership will also contribute to accelerating Genentech's "lab in a loop" approach, where experimental data informs computational models, leading to iterative development of better therapies.
Both companies will leverage publicly available and Genentech-proprietary data. Genentech will control the sharing of its proprietary data, and NVIDIA will not have direct access unless granted by Genentech for specific projects during the collaboration.
Overall, the collaboration aims to make drug development more predictable, cost-effective, and successful in the long term, ultimately contributing to the discovery and design of therapeutics to improve people's lives.
Source: businesswire.com
